Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7590647 | 0.91 | MAPT (0.40) | LTB4R2HCAR3ALDH1A1LMNAPOLB | |
| SCHEMBL7592924 | 0.91 | LTB4R2 (0.48) | LTB4R2HCAR3ALDH1A1TAS2R14 | |
| SCHEMBL7595995 | 0.90 | TAS2R14 (0.41) | LTB4R2HCAR3ALDH1A1LMNATAS2R14 | |
| SCHEMBL7595231 | 0.89 | ALDH1A1 (0.37) | LTB4R2HCAR3ALDH1A1TP53CYP1A2 | |
| SCHEMBL7591623 | 0.89 | LTB4R2 (0.40) | LTB4R2HCAR3ALDH1A1TP53CYP1A2 | |
| SCHEMBL7598805 | 0.87 | TSPO (0.43) | LTB4R2HCAR3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7590089 | 0.86 | TAS2R14 (0.42) | LTB4R2HCAR3ALDH1A1TP53CYP1A2 | |
| SCHEMBL7593000 | 0.86 | HCAR3 (0.42) | LTB4R2HCAR3ALDH1A1TP53 | |
| SCHEMBL7597825 | 0.85 | LTB4R2 (0.45) | LTB4R2HCAR3 | |
| SCHEMBL7596955 | 0.83 | HCAR3 (0.44) | HCAR3ALDH1A1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | LTB4R2 1901/4885HCAR3 3869/4885ALDH1A1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.